FIGHTING PROSTATE CANCER DIFFERENTLY

Science-driven development of diagnostics and therapeutics to specifically and efficiently treat prostate cancer. Diaprost is leading towards a different future.

Our mission

Diaprost´s research and development is targeting prostate cancer with ambition to revolutionize personalized medicine. The goal is to establish an antibody platform, for both in vivo diagnostic, to simplify and make the identification/detection of prostate cancer more reliable, as well as for targeted therapeutics.

Scientist viewing chemical experiment in laboratory
Laboratory

Our background

Diaprost was founded in 2005 based on the idea that the transformative success of the PSA assay for detection of prostate cancer could be leveraged as a personalized theranostic platform. The technology and patent applications were pursued by leading researchers at Lund University.

Diaprost is collaborating with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. Our scientists are active at some of the world´s most prominent centers in cancer research.

The team

Johan Drott

CEO

Åke Fredriksson

Chairman of the Board

Anders Axelsson

Board member

David Ulmert

Board member

Sven-Erik Strand

Board member

Daniel Thorek

Board member

Ann-Christin Malmborg

Board member

Jan Törnell

Board member

Places

Lund University

Sweden

Turku University

Finland

Memorial Sloan Kettering

USA

Johns Hopkins Hospital

USA

Contact

ADDRESS

Diaprost AB
SE-223 81 Lund

VISITING ADDRESS

Medicon Village
Scheelevägen 2, Lund

CONTACT

+46 709 22 41 40
johan.drott@diaprost.com